|
**Overview**: Orotic Acid Panel**Introduction**: The Orotic Acid Panel is a diagnostic tool designed to assess metabolic disorders using urine samples. In India, hereditary orotic aciduria (UMPS deficiency) is rare but treatable, presenting with megaloblastic anemia, growth failure, and orotic acid crystalluria; elevated urinary orotic acid also occurs secondary to urea cycle disorders or allopurinol challenge. High morbidity from under-testing in rural/low-SES children with unexplained anemia or failure to thrive, limited metabolic labs, delayed uridine supplementation leading to irreversible developmental delay. Per biochemistry practices aligned with ICMR and Indian Society for Inborn Errors of Metabolism guidelines, the test employs spectrophotometry for orotic acid, creatinine, and ratio over 1-2 days with high accuracy, valuable for confirming orotic aciduria or differentiating urea cycle defects. This diagnostic falls under metabolic screening and targets infants/children with megaloblastic anemia or suspected inborn errors, addressing accurate detection to guide uridine therapy or dietary management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise metabolic profiling and reducing rare disease burden. Its urine-based approach ensures reliable metabolite quantification.**Other Names**: Orotic Acid Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Urinary orotic acid standard for metabolic workup; in India, used in IEM centers.**Purpose**: The test assesses 3 parameters including orotic acid to guide metabolic disorder assessment, detect elevation, inform therapy.**Test Parameters**: 1. Orotic Acid, 2. Creatinine, 3. Orotic Acid/Creatinine Ratio.**Pretest Condition**: No fasting required; patients should have suspected metabolic disorder.**Specimen**: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on anemia, growth failure, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated metabolic disorder including delay, benefits of screening, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or renal impairment can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated orotic acid indicates UMPS deficiency or urea cycle defect, necessitating specialist input.**Specialist Consultation**: Pediatric metabolic specialists should be consulted for management.**Additional Supporting Tests**: Plasma amino acids, urine orotate confirmation.**Test Limitations**: Secondary elevations possible; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
